As of May 23, 2025, Clovis Oncology Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.08, this represents a potential upside of -205472.0%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -158461.5% |
| Potential Upside (10-year) | -205472.0% |
| Discount Rate (WACC) | 5.0% - 9.0% |
Revenue is projected to grow from $149 million in 12-2021 to $785 million by 12-2031, representing a compound annual growth rate of approximately 18.1%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2021 | 149 | 10% |
| 12-2022 | 217 | 46% |
| 12-2023 | 319 | 47% |
| 12-2024 | 377 | 18% |
| 12-2025 | 435 | 15% |
| 12-2026 | 493 | 13% |
| 12-2027 | 550 | 12% |
| 12-2028 | 598 | 9% |
| 12-2029 | 669 | 12% |
| 12-2030 | 724 | 8% |
| 12-2031 | 785 | 8% |
Net profit margin is expected to improve from -178% in 12-2021 to -171% by 12-2031, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2021 | (265) | -178% |
| 12-2022 | (384) | -177% |
| 12-2023 | (560) | -175% |
| 12-2024 | (657) | -174% |
| 12-2025 | (753) | -173% |
| 12-2026 | (848) | -172% |
| 12-2027 | (945) | -172% |
| 12-2028 | (1,026) | -172% |
| 12-2029 | (1,147) | -171% |
| 12-2030 | (1,239) | -171% |
| 12-2031 | (1,342) | -171% |
. Projected CapEx is expected to maintain at approximately 6% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2022 | 8 |
| 12-2023 | 12 |
| 12-2024 | 12 |
| 12-2025 | 16 |
| 12-2026 | 21 |
| 12-2027 | 25 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 59 |
| Days Inventory | 226 |
| Days Payables | 277 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2022 | (322) | (1) | 12 | 14 | (348) |
| 2023 | (469) | (1) | 18 | 16 | (502) |
| 2024 | (551) | (1) | 22 | 3 | (575) |
| 2025 | (630) | (1) | 25 | 11 | (665) |
| 2026 | (705) | (1) | 28 | 9 | (740) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -158461.5% |
| 10-Year DCF (Growth) | 0.00 | -205472.0% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Clovis Oncology Inc (CLVS) a buy or a sell? Clovis Oncology Inc is definitely a sell. Based on our DCF analysis, Clovis Oncology Inc (CLVS) appears to be overvalued with upside potential of -205472.0%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.08.